EXELA Pharma Sciences, LLC Announces the Launch of 8.4% Sodium Bicarbonate Injection, USP, 50mEq/50mL (1mEq/mL), in Partnerships with Premier and Civica Rx.
September 19, 2019 | Comments Off on EXELA Pharma Sciences, LLC Announces the Launch of 8.4% Sodium Bicarbonate Injection, USP, 50mEq/50mL (1mEq/mL), in Partnerships with Premier and Civica Rx.

Lenoir, NC September 11, 2019 – Exela Pharma Sciences is pleased to announce the launch of Sodium Bicarbonate Injection, USP. Exela received approval of its ANDA for Sodium Bicarbonate Injection in May for four separate presentations. The first presentation to launch will be the 8.4% Sodium Bicarbonate Injection, 50mEq/50mL (1mEq/mL) vials. This product has been on the FDA Drug Shortage list consistently and we are excited to be only the second FDA Approved Sodium Bicarbonate Injection on the US market. Exela will introduce shortly three additional presentations: an 8.4%, 10mEq/10mL (1mEq/mL) vial; a 7.5%, 44.6mEq/50mL (0.9mEq/mL) vial; and a 4.2%,
Read More